Diabetic Macular Edema Treated with Anti–Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers

Purpose To investigate central subfield thickness (CST) nonimprovers’ anatomic response in macular areas outside the central subfield and the time course of this response. Furthermore, to investigate the relationship between peripheral improvement and visual acuity. Design Retrospective study. Participants A total of 566 eyes in 566 patients with center-involved diabetic macular edema who initiated intravitreal treatment with ranibizumab between January 1, 2011 and December 31, 2013 in the Greater Copenhagen Region. Follow-up was completed at 2 years. Methods Patients were initially grouped as CST improvers and CST nonimprovers. The CST improvers had a ≥10% reduction in CST on ≥1 visit as opposed to CST nonimprovers with